Mark Cuban to join Trump at White House rollout of expanded TrumpRx drug initiative: report

Billionaire “Shark Tank” investor Mark Cuban is reportedly teaming up with President Donald Trump to expand the TrumpRx drug-pricing platform to include generic medications.Cuban was set to appear at a Monday afternoon White House announcement of the expansion — marking a pivot for one of the country’s most prominent Democrat-aligned business figures as Trump expands direct-to-consumer prescription-drug sales.News of Cuban’s expected appearance was reported by Bloomberg News.The move to add generic drugs to TrumpRx — which doesn’t sell medicine, but points consumers to websites that do — is part of a White House push to lower prescription-drug costs ahead of the midterm elections this fall.Through his Mark Cuban Cost Plus Drug Company, Cuban sells mail-order medications directly to consumers.He’s one of the country’s most outspoken critics of opaque pharmaceutical pricing systems.He was also a vocal critic of Trump’s during the 2024 presidential contest, when he endorsed Democratic candidate Kamala Harris.

“He’s fun to hang around.He’s got a great personality, he’s charismatic.

But I think he was a lousy president before, I think he’ll be a worse president this time,” he said of Trump on Fox Business in October 2024.The Post has sought comment from Cuban and the White House.The administration has been touting its agreements with drugmakers to lower prices for government programs and offer medications directly to consumers as part of a broader healthcare affordability push.TrumpRx, the federally run website launched earlier this year, advertises steep discounts on dozens of brand-name medications through “Most Favored Nation” pricing deals negotiated with pharmaceutical manufacturers.The site, which initially listed 43 branded drugs, currently lists 87 products ranging from diabetes and weight-loss medications to fertility treatments, cancer drugs and respiratory inhalers.It was not immediately known which generic drugs would b...